PTD-DBM
PTD-DBM (Protein Transduction Domain - Dishevelled Binding Motif)
Wnt Pathway Activator for Hair Growth
The information on this page is compiled from peer-reviewed research and is provided for educational and research purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Peptides discussed here may not be approved for human use in your jurisdiction. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.
What is PTD-DBM?
PTD-DBM is a synthetic fusion peptide combining two functional domains: a Protein Transduction Domain (PTD) and a Dishevelled Binding Motif (DBM). The PTD component enables the peptide to cross cell membranes, a capability that would otherwise require specialized delivery systems for intracellular targets. The DBM component is derived from a region of the CXXC5 protein that normally interacts with Dishevelled (Dvl), an upstream scaffolding protein in the Wnt signaling pathway. By combining these two functional units, PTD-DBM was designed to penetrate cells and interfere with a specific intracellular protein-protein interaction relevant to hair follicle biology.
The Wnt/beta-catenin pathway is essential for hair follicle development, maintenance, and cycling through its growth phases. In healthy hair follicles, active Wnt signaling promotes the anagen (growth) phase and supports follicle stem cell activity. The CXXC5 protein acts as a negative feedback regulator in this system by binding to Dishevelled and blocking downstream beta-catenin signaling. In androgenetic alopecia (male and female pattern hair loss), elevated CXXC5 expression (potentially driven by dihydrotestosterone-induced prostaglandin D2 signaling) suppresses Wnt activity and disrupts the hair cycle.
PTD-DBM functions by competitively disrupting the CXXC5-Dishevelled interaction [1]. By occupying the Dvl binding site, PTD-DBM prevents CXXC5 from exerting its inhibitory effect, allowing Wnt/beta-catenin signaling to proceed more robustly. Published research from Yonsei University (South Korea) demonstrated that topical application of PTD-DBM in mouse models promoted hair regrowth and extended the anagen phase [2]. When combined with valproic acid (a separate Wnt pathway activator) in animal models, PTD-DBM produced additive hair regrowth effects and also promoted wound-induced hair neogenesis (WIHN), the formation of new hair follicles in healing skin.
Research on PTD-DBM remains exclusively preclinical. No human clinical trials have been conducted or published as of early 2026. Published animal studies have not reported significant adverse effects, but the absence of human scalp data means that tolerance, long-term safety, and efficacy in the human hair cycle (which differs structurally from rodent fur cycling) are entirely uncharacterized.
Research Supply
Source high-purity PTD-DBM for your research
Dosage Guide
Route: Topical application to scalp (primary); subcutaneous or intradermal injection (investigational alternative)
Dosing Schedule
| Period | Dose |
|---|---|
| Animal research protocol (topical) | Daily or twice-daily topical application in aqueous solution or hydrogel carrier |
| Injectable (investigational) | 1-5 mg per session subcutaneous or intradermal |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|
Local vs. Systemic Injection
LOCAL INJECTION
Topical application to the scalp is the primary investigational delivery route, targeting hair follicles directly with limited systemic exposure
SYSTEMIC INJECTION
Injectable protocols (subcutaneous or intradermal) may produce systemic absorption with potential for off-target Wnt pathway activation in other tissues
Administration Tips
- Reconstitute lyophilized PTD-DBM with bacteriostatic water for injectable form; store at 2-8 degrees Celsius and use within 30 days
- For topical use, apply directly to affected scalp areas; penetration enhancers may improve delivery given the PTD component
- Often studied in combination with valproic acid for additive Wnt pathway activation
- No standardized human dose exists; concentration varies by supplier and formulation
- Do not apply to non-scalp areas (ocular area, mucous membranes)
Risks & Side Effects
Commonly Reported
Serious Risks
Wnt pathway hyperactivation
Beta-catenin accumulation is a driver of colorectal cancer, hepatocellular carcinoma, and other malignancies. The significance of localized topical activation in healthy individuals is unknown but warrants caution.
Systemic off-target Wnt activation
Injectable use may produce systemic absorption with off-target Wnt pathway activation in tissues beyond the scalp.
Scalp folliculitis or infection
Risk at injection sites with injectable protocols.
Unknown consequences of sustained anagen extension
The long-term consequences of sustained anagen phase extension in the human hair cycle have not been characterized.
Contraindications
- Personal or family history of Wnt-pathway-associated malignancies (colorectal cancer, hepatocellular carcinoma, Wilms tumor)
- Active skin infection, eczema, psoriasis, or dermatitis at the application site
- Pregnancy or breastfeeding (no safety data; Wnt pathway is essential for embryonic development and interference is contraindicated)
- Known hypersensitivity to PTD-DBM or any component of the formulation
- Use on non-scalp areas (ocular area, mucous membranes) is not appropriate
Related Peptides
Experts Covering PTD-DBM
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. PTD-DBM has not been approved by the FDA for any medical condition. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.
Frequently Asked Questions
What is PTD-DBM and how does it promote hair growth?
Does PTD-DBM work for hair loss?
How is PTD-DBM applied for hair growth?
What are PTD-DBM side effects?
Is PTD-DBM safe for long-term use?
Can PTD-DBM be combined with other hair loss treatments?
References
- Kim HY, Yoon JY, Yun JH, et al.. CXXC5 is a negative-feedback regulator of the Wnt/beta-catenin pathway involved in osteoblast differentiation. Cell Death Differ. 2015. PMID 25633194
- Lee SH, Seo SH, Lee DH, et al.. Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. J Invest Dermatol. 2017. PMID 28595998
- Kim HY, Choi S, Yoon JH, et al.. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016. PMID 26941261